Kirsty Cuthill

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus et al. · The Lancet Haematology · 2022 · 136 citations · Full text

Life Sciences, Hematology, Immunology +14

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

Jelena Jovanović, Adam Ivey, Alessandro M. Vannucchi et al. · Leukemia · 2013 · 106 citations · Full text

Medicine, Hematology, Molecular Biology +15

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

Jonathan Sive, Kirsty Cuthill, Hannah Hunter et al. · British Journal of Haematology · 2021 · 56 citations

Medicine, Hematology, Internal Medicine +17

Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration

Marta Pasikowska, Elisabeth Walsby, Benedetta Apollonio et al. · Blood · 2016 · 39 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Ana M. Metelo, Agnieszka Jóźwik, Le Anh Luong et al. · Cancer Research Communications · 2022 · 39 citations · Full text

Life Sciences, Cell Biology, Immunology +17